NRG-HN003 Archives - NRG Oncology

‘NRG-HN003 Documentation’ of page ‘NRG-HN003’

Safety Reports Nivolumab, Ipilimumab, Cabozantinib – posted 12/2/2019Blinatumomab, Nivolumab – posted 12/2/2019Pembrolizumab, Entinostat – posted 11/18/2019 Pembrolizumab – posted 10/21/2019 Pembrolizumab – posted 10/7/2019 Pembrolizumab, Entinostat – posted 9/9/2019 Pembrolizumab, Mogamulizumab – posted 9/9/2019 Pembrolizumab – posted 9/3/2019 Pembrolizumab – posted 8/12/2019 Pembrolizumab, VEGF-Trap, AVE 0005 – posted 7/29/2019 Mogamulizumab, Pembrolizumab – posted 7/8/2019 Pembrolizumab […]

‘NRG-HN003: A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)’ of page ‘NRG-HN003’

Principal Investigator Julie E. Bauman, MD, MPH Primary Objective To determine the recommended phase II schedule for the combination of MK-3475 (pembrolizumab) and standard, adjuvant cisplatin-radiotherapy in patients with high-risk, HPV-negative head and neck squamous cell carcinoma, based upon dose-limiting toxicity. Patient Population Patients with stage III-IVb, high-risk squamous cell carcinoma of the oral cavity, […]

Content Block Tag: NRG-HN003

‘NRG-HN003 Documentation’ of page ‘NRG-HN003’

‘NRG-HN003: A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)’ of page ‘NRG-HN003’